艾司奥美拉唑联合曲美布汀治疗无效食管动力致胃食管反流病患者的效果

目的:观察艾司奥美拉唑联合曲美布汀治疗无效食管动力(IEM)致胃食管返流病(GERD)患者的效果。方法:选取58例IEM所致的GERD患者作为研究对象,以随机数字表法将其分为观察组28例和对照组30例。对照组采用艾司奥美拉唑治疗,观察组在对照组基础上联合曲美布汀治疗,比较两组治疗前后胃食管反流病(GERD Q)问卷评分、食管体部蠕动收缩波幅、食管远端收缩积分(DCI)、湿咽成功率和不良反应发生率。结果:治疗后,观察组GERD Q问卷评分、血清白细胞介素-17水平和白细胞介素-6水平均低于对照组,近端、中端和远端各蠕动收缩波幅、DCI、湿咽成功率均高于对照组,差异有统计学意义(P<0.05);对照组治疗前后近端、中端和远端各蠕动收缩波幅、DCI、湿咽成功率比较,差异均无统计学意义(P>0.05)。结论:艾司奥美拉唑联合曲美布汀治疗IEM所致的GERD患者可增大食管体部蠕动收缩波幅,提高DCI和湿咽成功率,降低GERD Q问卷评分和血清炎性因子水平,效果优于单纯艾司奥美拉唑治疗。

Effects of Esomeprazole combined with Trimebutine in treatment of patients with gastroesophageal reflux disease caused by ineffective esophageal motility

Objective:To investigate effects of Esomeprazole combined with Trimebutine in treatment of patients with gastroesophageal reflux disease(GERD)caused by ineffective esophageal motility(IEM).Methods:58 patients with GERD caused by IEM were selected as the research objects,and were divided into observation group(28 cases)and control group(30 cases)by using the random number table method.The control group was treated with Esomeprazole,while the observation group was treated with Trimebutine on the basis of that of the control group.The score of gastroesophageal reflux disease questionnaire(GERD Q),esophageal body peristaltic contraction amplitude,distal esophageal contraction integral(DCI),success rate of wet pharynx and incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the GERD Q questionnaire score and the levels of the serum interleukin-17 and interleukin-6 in the observation group were lower than those in the control group;the proximal,mid,and distal peristaltic contraction amplitudes,DCI,and success rate of wet pharynx were all greater than those of the control group;and the differences were statistically significant(P<0.05).In the control group,there were no significant differences in the proximal,middle and distal peristaltic contraction amplitudes,DCI,and wet pharynx success rate before and after the treatment(P>0.05).Conclusions:Esomeprazole combined with Trimebutine in the treatment of the GERD patients caused by IEM can increase the esophageal body peristaltic contraction amplitude,increase DCI and the success rate of wet pharynx,and reduce the GERD Q questionnaire score and the serum inflammatory factor levels.Moreover,it is superior to single Esomeprazole treatment.